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Abstract
Background: HER-2 gene testing has become an integral part of breast cancer patient diagnosis. The most commonly
used assay in the clinical setting for evaluating HER-2 status is immunohistochemistry (IHC) and fluorescence in situ
hybridization (FISH). These procedures permit correlation between HER-2 expression and morphological features.
However, FISH signals are labile and fade over time, making post-revision of the tumor difficult. CISH (chromogenic in
situ hybridization) is an alternative procedure, with certain advantages, although still limited as a diagnostic tool in breast
carcinomas.
Methods: To elucidate the molecular profile of HER-2 status, mRNA and protein expression in 75 invasive breast
carcinomas were analyzed by real time quantitative RT-PCR (qRT-PCR) and IHC, respectively. Amplifications were
evaluated in 43 of these cases by CISH and in 11 by FISH.
Results: The concordance rate between IHC and qRT-PCR results was 78.9%, and 94.6% for qRT-PCR and CISH.
Intratumoral heterogeneity of HER-2 status was identified in three cases by CISH. The results of the three procedures
were compared and showed a concordance rate of 83.8%; higher discordances were observed in 0 or 1+ immunostaining
cases, which showed high-level amplification (15.4%) and HER-2  transcript overexpression (20%). Moreover, 2+
immunostaining cases presented nonamplified status (50%) by CISH and HER-2 downexpression (38.5%) by qRT-PCR. In
general, concordance occurred between qRT-PCR and CISH results. A high concordance was observed between CISH/
qRT-PCR and FISH. Comparisons with clinicopathological data revealed a significant association between HER-2
downexpression and the involvement of less than four lymph nodes (P = 0.0350).
Conclusion: Based on these findings, qRT-PCR was more precise and reproducible than IHC. Furthermore, CISH was
revealed as an alternative and useful procedure for investigating amplifications involving the HER-2 gene.
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Background
In breast cancer, the assays routinely used in clinical prac-
tice are those that address a specific management deci-
sion. Hormonal therapy is based on estrogen receptor
(ESR) and progesterone receptor (PGR) status. Trastuzu-
mab (Herceptin™, Genentech, Inc, San Francisco, CA,
USA) therapy, a humanized monoclonal antibody, is
based on HER-2 status.
ERBB2/HER-2  (HER-2/neu,  NEU,  NGL,  HER2,  TKR1,
CD340) encodes a membrane receptor protein in the
growth factor receptor gene family presenting tyrosine
kinase activity [1,2]. HER-2 plays a role in the pathogene-
sis of a significant number of human tumors. It is altered
in approximately 20–30% of breast carcinomas and this is
manifested as gene amplification and/or protein overex-
pression [3-5]. These alterations are associated with a
shorter disease free period and overall survival and with
resistance to tamoxifen antiestrogen therapy and other
chemotherapy regimens, regardless of the nodal or hor-
mone receptor status [3,4,6,7]. Moreover, breast carci-
noma patients presenting HER-2  amplification or
overexpression can benefit from anthracycline-based regi-
mens, as well as trastuzumab [8].
The therapy choice for breast cancer patients depends on
the discrimination of HER-2 status. Reliable laboratory
data in evaluating HER-2 status is essential, because the
treatment is beneficial for advanced breast cancer and
avoids potential cardiotoxic effects in women not show-
ing amplification and overexpression [9]. The most com-
monly used assay in the clinical setting for evaluating
HER-2 status is immunohistochemistry (IHC) and fluo-
rescence in situ hybridization (FISH), both approved by
the FDA (U.S. Food and Drug Administration). More
recently, the CISH (chromogenic in situ hybridization)
methodology, also approved by FDA, has emerged as a
potential alternative to FISH. When compared with FISH,
CISH has been described as having several advantages.
CISH does not require an expensive fluorescence micro-
scope with multi-band-pass filters, it produces a perma-
nent staining and samples can be archived indefinitely,
thus avoiding archival recording with an expensive CDD
camera. The morphology is easier to analyze, particularly
for distinguishing invasive cancer cells and in situ compo-
nents. Moreover, tumor heterogeneity is promptly identi-
fied, even at low magnification (20×) [10-13]. In FISH
analysis, tissue morphology and gene amplification are
primarily disconnected because of tumor cells for signal
evaluation are based on nuclear DAPI (4', 6-Diamidino-2-
phenylindole) or propidium iodide staining, which does
not always permit adequate histopathological evaluation
of the cells [14]. CISH is a useful methodology for con-
firming ambiguous IHC results [11]. In addition,
polymerase chain reaction (PCR) based technology has
been demonstrated to successfully evaluate specific
mRNAs, especially those present in low copy numbers in
a small number of cells or in small quantities of tissue,
and mRNAs expressed in mixed-cell populations. Quanti-
tative real time reverse transcript PCR (qRT-PCR) is a
quantitative method easily amenable to standardization.
However, qRT-PCR suffers from the same drawback as
other PCR-based methods. The tumor cell population
within the tissue under evaluation must be isolated, the
template quality, operator variability, subjectivity in data
analysis and reporting are technical aspects that must be
considered [14,15]. This procedure is an alternative for
scoring HER-2 status in human breast cancer. Limitations
based on tumor heterogeneity and amplification of HER-
2 in noninvasive cancer can be eliminated by the use of
laser microdissection, although this seems to be impracti-
cable for routine diagnosis [14].
The purpose of the current study was to assess agreement
between gene amplification detection by CISH and tran-
script (qRT-PCR) and protein (IHC) expression, as well as
to evaluate their relevance for determining HER-2 status
in breast carcinomas. In addition, the data were correlated
with clinicopathological features, such as tumor size,
lymph node status, histological grade and Ki-67 status.
Methods
Patients
Seventy-five breast carcinoma samples were obtained
between 2000 and 2004, from Amaral Carvalho Hospital,
Jaú (SP, Brazil). The patients were accrued consecutively
and the criterion for inclusion in the study was no previ-
ous histological diagnosis of breast cancer. Patients under-
went segmental resection or mastectomy and none of
them had received radiotherapy or chemotherapy prior to
surgery. All patients were advised of the procedures and
provided written informed consent. The Ethics Commit-
tee from Amaral Carvalho Hospital Foundation approved
this study (CEPFHAC 007/05).
Seventy tumors were infiltrating ductal and five infiltrat-
ing lobular carcinomas, in which most presented operable
stage II and III breast cancer and positive axillary lymph
nodes. Most patients were more than 50 years-old (64%)
with a mean of 58 ± 15.5 years (range, 30–94 years); most
tumors were more than 2 cm (73.3%) and half of them
showed low Ki-67 positivity. The mean follow-up was
49.8 ± 20.1 months (varying between 23 to 83 months).
During this interval, five patients died due to unrelated
causes, two patients presented recurrence in the same
breast, eight presented metastasis (two spreading to the
bone and six to the lung) and six missed their follow-ups.
Patients with a family history of cancer were noted, partic-
ularly among first-degree and second-degree relatives, and
whenever possible, the cancer was confirmed with docu-BMC Cancer 2009, 9:90 http://www.biomedcentral.com/1471-2407/9/90
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mented medical records or ascertained from the death cer-
tificate (Table 1). The patients received different
chemotherapy treatments: AC (adriamycin, cyclophos-
phamide); FEC (5-fluorouracil, 4-epirubicin, cyclophos-
phamide); FAC (5-fluorouracil, adriamycin,
cyclophosphamide); CMF (cyclophosphamide, meth-
otrexate, 5-fluorouracil), at 100% or 70% of the dose,
according to the age and clinical status of the patient.
Fifty-five patients (73%) received radiotherapy and 51
ESR1 positive and/or PGR positive cases (68%), as deter-
mined by IHC analysis, were treated with tamoxifen (20
mg/day) for 60 months at the end of the chemotherapy
treatment. Some patients presenting intolerance or side
effects (postmenopausal) were treated with aromatase
inhibitors, such as anastrozole (1 mg/day) or letrozole
(2.5 mg/day).
Histopathological classification was performed according
to the WHO International Classification of Disease for
Oncology [16] and clinical stage was determined accord-
ing to the UICC TNM classification [17]. The malignancy
of infiltrating carcinomas was scored according to the
Scarff-Bloom and Richardson grading system [18].
HER-2 copy number alterations
In 43 out of 75 samples that presented available histolog-
ical sections, CISH analysis was performed (32 additional
cases are part of the Hospital's sample bank especially
devoted to diagnosis). Eleven cases that presented ade-
quate tumor samples on slides were evaluated by dual
color FISH. CISH and FISH were carried out on 4 μm thick
archival formalin fixed paraffin embedded tumour sam-
ples using a Zymed SPoT-Light HER2 CISH Kit (Zymed
Laboratories Inc, San Francisco, CA) and a HER2 FISH
pharmDxTM  Kit (DakoCytomation, Denmark), respec-
tively, according to manufacturers' instructions. At least
200 non-overlapping tumor cell nuclei were evaluated by
CISH. According to the manufacturer's instructions, the
Table 1: Comparison of clinicopathological features with HER-2 status using CISH, qRT-PCR (qPCR), and IHC.
Variables (n)a CISH P * qPCR P * IHC P *
≤ 5> 1 0 ≤ 2.00 >2.00 0/1+ 2/3+
Age (years)
≤ 50 (28) 9 5 0.9541 15 13 0.2569 17 11 0.3651
>50 (48) 15 8 32 16 34 14
Lymph node status
<4 (57) 21 9 0.1756 38 19 0.0915 40 17 0.4723
≥ 4 (32) 3 4 8 10 11 7
ND (1) 0 0 0 1 0 1
Tumor Size (cm)
0 – 2 (19) 5 5 0.1883 10 9 0.2953 11 8 0.2745
>2 (56) 19 7 37 19 40 16
ND (1) 0 1 0 1 0 1
Clinical Stage
I/IIA/IIB (65) 21 9 0.1756 41 24 0.5901 44 21 0.7912
IIIA/IIIB (11) 3 4 6 5 7 4
Histologic grade
I/II (36) 10 6 1.000 22 14 0.9237 23 13 0.6767
III (35) 10 6 21 14 24 11
ND (5) 4 1 4 1 4 1
Ki-67 status
Low (≤ 25%) (32) 11 6 0.5133 19 13 0.5354 21 11 0.7209
High (> 25%) (31) 8 7 16 15 19 12
Not reactive (13) 5 0 12 1 11 2
Familial History of Cancer
Yes (15) 4 3 0.6346 7 8 0.1769 10 5 0.9678
No (61) 20 10 40 21 41 20
a Number of the cases evaluated by qRT-PCR and IHC, while 37 cases were evaluated using CISH.
* Chi-Square test.
ND: not determined.BMC Cancer 2009, 9:90 http://www.biomedcentral.com/1471-2407/9/90
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tumors were classified depending on the number of HER-
2 gene copies in the nuclei as: (a) nonamplified, those
tumor cells with two to five brown intranuclear spots per
nucleus; (b) low-level amplification, when six to 10 sig-
nals per nucleus were detected in more than 50% of
tumor cells or when a small coalescing signal cluster was
found; (c) high-level amplification, defined as more than
10 copies per nucleus or when copy clusters were
observed in more than 50% of cancer cells.
By FISH, HER-2 and chromosome 17 centromere signals
were counted in at least 60 nuclei; a HER-2/CEP-17 ratio
≥ 2.0 was considered positive for HER-2 gene amplifica-
tion [19]. A fluorescence microscope (Olympus AX61,
Olympus Optical, Hamburg, Germany), equipped with a
CCD camera (Photometrics CH 250, Huntington Beach,
CA) was used. Image analysis was performed with the
software Applied Spectral Imaging CGH View 3.0 (Olym-
pus).
Slides from both procedures were randomly distributed to
three independent blinded observers (SMS, CGTS, and
NAB). Any discrepancy in sample classification was
addressed by immediate review and the final result was
reached by consensus. In addition, different individually
identified tumor areas were analyzed.
Isolation of tumoral cells by microdissection
Immediately after surgery, the tumor samples were frozen
at -80°C. Eight successive unstained slides from frozen
samples were prepared using a cryostat and stored at -
80°C. The first and the last slides were stained with hema-
toxylin-eosin for histopathological evaluation. Tumoral
components were precisely outlined and labeled under
the microscope. The defined areas were retrieved by man-
ual microdissection. To minimize dilution of the PCR sig-
nal by nontumoral and nonamplified cells, sections
containing at least 90% tumor cells were selected for RNA
extraction.
Total RNA isolation and reverse transcription
Total RNA was extracted from pulverized frozen tumor tis-
sue using the Rneasy mini Kit (Qiagen GmbH, Hilden,
Germany), according to the manufacturer's instructions.
Reverse transcription using SuperScript™ II reverse tran-
scriptase (Invitrogen Life Technologies Inc., Carlsbad, CA)
was carried out for 60 min at 42°C and the reaction mix-
ture was subsequently inactivated for 15 min at 70°C as
previously described [20]. The cDNA was stored at -70°C.
Real time quantitative RT-PCR (qRT-PCR)
Seventy-five breast carcinomas were evaluated by qRT-
PCR. Four normal breast tissue samples from patients
who underwent mammary reduction and confirmed as
histopathologically normal were used as controls. PCR
amplification was performed in an ABI Prism 7000
Sequence Detection System (Applied Biosystems, Foster
City, CA, USA). Primers and TaqMan probes for HER-2
and the GAPDH control reference gene were designed and
synthesized according to Taqman Gene Expression Assay
(assays Hs00170433_m1 and 4326317E, respectively)
(Applied Biosystems, Foster City, CA, USA). Quantitative
data was analyzed using the Sequence Detection System
software (v1.0; Applied Biosystems). PCR reactions were
carried out in a total volume of 10 μL, according the man-
ufacturer's instructions. A relative standard curve was con-
structed for all primers with serial dilutions of placenta
cDNA (100, 50, 25, 12.5, and 8 ng/uL). The standard
curves of the target and reference genes showed similar
results of efficacy (>90%). The reactions were performed
in duplicate. The relative quantification (RQ) was given
by the ratio between the mean value of the target gene and
the mean value of the reference gene (GAPDH) in each
sample. The relative amount of PCR product generated
from each primer set was determined on the basis of the
cycle threshold (Ct) value. The RQ was calculated by 2-
ΔΔCT [21]. HER-2 relative expression level was compared
with the ratio of healthy controls. Overexpression was
defined as the mean HER-2/reference gene ratio RQ>2.00.
Immunohistochemistry (IHC)
HER-2 protein levels were performed using rabbit mono-
clonal antibody (SP3 Clone) (Thermo Fisher Scientific,
Fremont, CA, USA) (dilution 1:100) in 75 cases. After
incubation for one hour, the sections were washed in PBS,
incubated for 30 min with secondary biotinylated anti-
body and treated for 30 min with streptavidin peroxidase
complex (LSAB, DAKO, Carpinteria, CA, USA). The sec-
tions were developed with 3,3'-diaminobenzidine (DAB)
and counterstained with hematoxylin. Negative and posi-
tive control slides were included in each assay. The results
were scored as: (0) no immunoreactivity; (1+) weak and
incomplete immunoreactivity; (2+) weak and complete
membrane immunoreactivity in more than 10% of the
tumor cells or strong and complete membrane immuno-
reactivity in less than 10% of the tumor cells; and (3+)
strong and complete membrane immunoreactivity in
more than 10% of the tumor cells. Slides were randomly
distributed to two independent blinded observers (FAMN
and MACD). Only the invasive component of the neopla-
sia was assessed and scored. The level of Ki-67 was evalu-
ated in all cases, but 13 cases were nonreactive. Ki-67,
ESR1, and PGR protein expression was performed as
described by Rosa et al. [20].
Statistical Analysis
Comparisons between HER-2 expression (qRT-PCR and
IHC), gene copy number (CISH) and several clinico-
pathological features were calculated using the Chi square
test. Six patients that missed follow-up were censored as
survivors in the statistical calculations. The correlation
between the three methodologies was evaluated usingBMC Cancer 2009, 9:90 http://www.biomedcentral.com/1471-2407/9/90
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One-way Analysis of Variance (ANOVA); differences were
tested for significance by the Mann-Whitney test for two
categories and by the Kruskal-Wallis test for three catego-
ries. Statistical significance was designated at P < 0.05. The
concordance rate was obtained considering: (a) amplifica-
tion by CISH and  transcript overexpression (RQ>2.00)
and 2+ or 3+ immunostaining; (b) nonamplification by
CISH and transcript downexpression (RQ ≤ 2.00) and 0 or
1+ immunostaining.
Results
Breast cancer samples were assessed by HER-2 gene ampli-
fication and protein expression in histological samples
using CISH and IHC, respectively (Figure 1). Transcript
expression was evaluated by qRT-PCR in fresh samples
after microdissection. HER-2 data obtained in all the pro-
cedures are shown in Tables 2 and 3.
CISH was performed on 43 cytological samples; in three
of these cases the spots presented inconclusive results; the
brown spots were undistinguished. Twenty-four out of 37
tumors (64.9%) were not amplified by CISH, while 13
samples (35.1%) showed high-level HER-2 amplification.
Different areas of the tumor were evaluated and the final
analysis showed agreement, except in three cases (Figure
2A–C). Case A presented an equivalent number of non-
amplified cells (2 copies and 3–5 copies) in area 1 and
more than 50% of the cells with high-level amplification
in area 2 (this case presented 0 score by IHC and normal
expression level by qRT-PCR). Case B showed nonampli-
fied cells in both areas, but in area 2, low-level and high-
level amplification cells were also observed (IHC, 0 score;
qRT-PCR, overexpression). Case C showed preferentially
nonamplified cells; however, in area 1, cells with 3–5 cop-
ies were predominant and in area 2, a prevalence of two
HER-2 copies was detected and the presence of sporadic
cells with high-level amplification was also found (IHC,
3+ score; qRT-PCR, overexpression). More than 400 cells
were evaluated for each of these cases. In the other sam-
ples (37 cases), the nuclear features were maintained, the
morphological details were apparent and large gene copy
clusters were easily detected at low magnification. Normal
epithelial cells and lymphocytes showed one or two HER-
2 signals per nucleus.
HER-2 amplification status by FISH was evaluated in 11
out of 43 cases investigated by CISH. The comparison
between CISH and FISH revealed agreement in eight cases
that presented high-level HER-2  amplification. These
cases presented scores 2+ (two cases) and 3+ (six cases) by
IHC. Only one of them, identified as amplified by CISH,
showed sporadic cells (<10% of the cells) with poly-
ploidy. The three cases that presented heterogeneity in
two different areas of the tumor by CISH were also evalu-
ated by FISH (Figure 2A–C). Case A presented similar
results to that observed in the area 1 detected by CISH;
Breast cancer cells showing immunohistochemistry and chromogen in situ hybridization results of HER-2 Figure 1
Breast cancer cells showing immunohistochemistry and chromogen in situ hybridization results of HER-2. (A-D) 
IHC: HER-2 protein expression scored as 0 (A), 1+ (B), 2+ (C), and 3+ (D); (E-H) CISH: HER-2 gene detected in nuclei with 
two signals (E), more than two signals (F), and high-level amplification (G-H).BMC Cancer 2009, 9:90 http://www.biomedcentral.com/1471-2407/9/90
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amplification was observed in only 10% of the cells. Cases
B and C showed principally no amplification by FISH,
comparable to that detected by CISH (case B: 90% of the
tumoral cells were not amplified and 10% presented poly-
ploidy; case C: no amplification in 90% of the cells and
amplification in 10%). An overall concordance between
CISH and FISH results was found.
HER-2 relative expression level was evaluated in 75 sam-
ples by qRT-PCR in comparison with four healthy breast
tissue and ranged between RQ = 0.05 to 20.43. Overex-
pression (RQ>2.00) was observed in 29 out of 75 cases
(38.7%).
Among the 75 cases analyzed by IHC, 50 (66.7%) pre-
sented a score of 0 or 1+. The 2+ immunostaining cases
comprised 13 samples (17.3%) and 12 cases (16.0%) pre-
sented 3+ scoring.
CISH/FISH compared to IHC analysis
Four out of 26 cases (15.4%) presenting 0 or 1+ immu-
nostaining scores showed high-level amplification by
CISH. Two out of four samples (50%) scored as 2+ pre-
sented high-level amplification by CISH. All cases present-
ing 3+ scoring showed amplification by CISH (Table 2).
The concordance rate between CISH and IHC was 83.8%
(31 cases). Eight cases scored as 2+/3+ evaluated by FISH
showed amplification.
qRT-PCR compared to IHC results
HER-2 transcript levels were significantly lower in cases
presenting low protein expression (0 or 1+) than in cases
presenting high expression (3+) (Figure 3A). Ten out of 50
cases (20%) presenting a score of 0 or 1+ showed overex-
pression by qRT-PCR. Seven out of 12 samples (58.3%)
comprising 2+ immunostaining showed overexpression
by qRT-PCR. Twelve out of 13 cases (92.3%) which pre-
Table 2: Comparison between protein expression by IHC and gene amplification by CISH and FISH.
CISH (n = 37) FISH (n = 8)
IHC No amplification (%) High amplification (%) No amplification (%) Amplification (%)
0 or 1+ 22 (84.6) 4 (15.4) 0 (0.0) 0 (0.0)
2+ 2 (50.0) 2 (50.0) 0 (0.0) 2 (25.0)
3+ 0 (0.0) 7 (100) 0 (0.0) 6 (75.0)
Total 24 13 0 8
Table 3: Transcript expression by qRT-PCR in relation to protein expression and gene amplification using IHC and CISH/FISH 
methodologies, respectively.
qRT-PCR







0 or 1+ 50 (66.7) 0.93 (0.05–12.24) <0.0001a 40 (80.0) 10 (20.0)
2+ 12 (17.3) 2.46 (1.15–7.61) 5 (41.7) 7 (58.3)
3+ 13 (16.0) 7.55 (1.07–20.43) 1 (7.7) 12 (92.3)
Total 75
CISH
No amplification 24 (64.9) 0.75 (0.05–1.95) <0.0001b 24 (100) 0 (0.0)
High amplification 13 (35.1) 4.69 (1.07–20.43) 2 (15.4) 11 (84.6)
Total 37
FISH
No amplification 0 (0.0) 0 (0.0) ND 0 (0.0) 0 (0.0)
Amplification 8 (100) 7.93 (2.64–20.43) 0 (0.0) 8 (100)
Total 8
* Mean HER-2/reference gene ratios; ND: not determined.
a Kruskal-Wallis test.
b Mann-Whitney test.BMC Cancer 2009, 9:90 http://www.biomedcentral.com/1471-2407/9/90
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sented a score of 3+ overexpressed HER-2 transcript (Table
3). Concordance between qRT-PCR and IHC was
observed in 59 cases (78.7%).
qRT-PCR compared to CISH/FISH analysis
Concordance between qRT-PCR and CISH was observed
in 35 cases (94.6%). HER-2  mRNA levels were signifi-
cantly lower in nonamplified cases by CISH (Figure 3B).
None of the 24 nonamplified cases by CISH showed HER-
2  overexpression. Eleven out of 13 cases (84.6%) pre-
sented both, high-level amplification and HER-2 overex-
pression by qRT-PCR. All cases showed HER-2
overexpression and amplification by FISH (Table 3).
Among the 37 cases evaluated by all three methodologies
(CISH, qRT-PCR, and IHC), 31 (83.8%) showed concord-
ance. Discrepancies were found in six cases; four cases 0 or
1+ by IHC showed HER-2 gene overexpression and were
amplified by CISH; and two cases 2+ by IHC showed
HER-2 gene RQ ≤ 2.00 and were not amplified by CISH
(Figure 3C).
Clinico-pathological data in comparison with HER-2 
status
HER-2  data were also compared to clinicopathological
features (Table 1). No statistical correlation was observed
with age, tumor size, clinical stage, histological grade, Ki-
67 status or familial history of cancer. A marginally signif-
icant correlation with lymph node status was detected:
82.6% of the cases presenting RQ ≤ 2.00 showed less than
four positive lymph nodes (P = 0.0915). Comparison of
individual HER-2 relative quantification values between
the two classes of lymph node status (<4 and ≥ 4) showed
a significant correlation (P  = 0.0350), confirming the
association between cases presenting RQ ≤ 2.00 and the
involvement of less than four positive lymph nodes (Fig-
ure 4).
In the four lobular carcinomas evaluated by all three
methodologies (CISH, qRT-PCR, and IHC), two presented
discordant results: one case showed high-level amplifica-
tion by CISH, HER-2 overexpression by qRT-PCR and neg-
ative immunostaining; the other sample presented
nonamplified by CISH, RQ ≤ 2.00 by qRT-PCR and 2+
immunostaining by IHC analysis. The two remaining
cases were nonamplified, RQ ≤ 2.00 and negative immu-
nostaining. The case evaluated exclusively by qRT-PCR
and IHC presented RQ ≤ 2.00 and negative immunostain-
ing. Individual values of HER-2 expression by qRT-PCR
were compared between ductal and lobular carcinomas
and no significant association was observed (median RQ
= 1.34 ± 3.83 and RQ = 1.7 ± 1.02, respectively; P  =
0.7375, data not shown).
Discussion
HER-2 gene has been extensively studied as a prognostic
and predictive marker in clinical breast cancer, making
this receptor a valuable target for the treatment of human
breast cancer [22]. HER-2 status is predominantly evalu-
ated by IHC staining, because it is easy to perform and
presents a relatively low cost. However, a wide range of
sensitivity and specificity was observed among various
commercially available antibodies [23]. In addition, FISH
is used for those cases that are scored as 2+. The advantage
of FISH testing is that the quantitative interpretation of
results with experience is relatively straightforward and
concordance rates among observers are higher than with
IHC in some studies [for review, [19]]. CISH is an alterna-
tive method to evaluate amplifications that requires a con-
ventional light microscopy, permits a more rapid
interpretation time and a review of the morphological
details. A further advantage of CISH is that the probe sig-
nals are permanent and the slides can therefore be
archived for long periods of time [24]. Data do not clearly
demonstrate the superiority of either IHC or in situ
hybridization (ISH) as a predictor of beneficial effects
from anti-HER-2 therapy after validated testing has been
Intratumoral heterogeneity of HER-2 gene status detected by  chromogen in situ hybridization in two different areas (areas  1 and 2) from three breast tumors (A, B, and C) Figure 2
Intratumoral heterogeneity of HER-2 gene status 
detected by chromogen in situ hybridization in two 
different areas (areas 1 and 2) from three breast 
tumors (A, B, and C). Nonamplified HER-2 gene (2–5 cop-
ies per nucleus), low-level amplification (6–10 copies or small 
clusters) and high-level amplification (>10 copies or large 
clusters) were observed in different areas from the same 
tumor. FISH results of the same cases are represented on 
the right side of the figure.BMC Cancer 2009, 9:90 http://www.biomedcentral.com/1471-2407/9/90
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(A) Association between transcript and protein (1+, 2+, and 3+) expression levels; (B) Correlation between transcript expres- sion level and amplification (2–5 copies and >10 copies or large clusters); (C) CISH, IHC and qRT-PCR results in 37 samples of  breast cancer Figure 3
(A) Association between transcript and protein (1+, 2+, and 3+) expression levels; (B) Correlation between 
transcript expression level and amplification (2–5 copies and >10 copies or large clusters); (C) CISH, IHC and 
qRT-PCR results in 37 samples of breast cancer. The samples are indicated in dark circles. The transcript expression val-
ues by qRT-PCR are indicated in a log scale. Bars indicate the median value. P values are shown.BMC Cancer 2009, 9:90 http://www.biomedcentral.com/1471-2407/9/90
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carefully performed [25]. Quantitative real time PCR has
the potential to become standard in terms of its perform-
ance, accuracy, sensitivity, broad dynamic range and high
throughput capacity [26,27].
Concordance between FISH and CISH was 100% for the
eight cases analyzed. This high concordance was also
found by several other studies [11,14,28]. One of the
eight cases displayed a small frequency of cells showing
chromosome 17 polysomy by FISH and showed a score
2+ by IHC. Peiró et al. [29] showed that all of the poly-
ploidy tumors analyzed presented 2+ immunostaining.
Although a limited number of cases were evaluated by
FISH in the present study, the data are in agreement with
other studies which indicate that the chromogenic ISH
technique seems to be sensitive and specific for the detec-
tion of HER-2  amplification in human archival tumor
samples [14,28].
CISH analysis revealed intratumoral heterogeneity in
three cases. In case A, 50% of cells showed high-level
amplification and nonamplified cells. In addition, this
case showed discordant data between IHC and qRT-PCR
methodologies, probably due to qRT-PCR false-positive
results. The major question is whether cells showing dif-
ferent levels of amplification make any difference or
whether a threshold (or its value) percentage of amplified
tumor cells is required to define nonamplified and ampli-
fied tumors. Regardless of the CISH results, these three
patients were treated with tamoxifen and radiotherapy
(patients A and B) and radiotherapy and CMF (patient C),
according to the IHC results. The outcome was favorable
for more than 45 months. Further studies should be per-
formed to clarify the tumoral heterogeneity involving
HER-2 amplifications in breast cancer. These three cases
were evaluated by FISH and similar results were observed
between CISH and FISH analysis for all the cases. When
using FISH, it was not possible to determine the two areas
observed by CISH, probably due to the restricted number
of cells evaluated. Case A presented a higher frequency of
amplified cells by CISH in its area 2 than that observed by
FISH. Specifically in this case, the paraffin sections used
for CISH and FISH methods were not successive and, most
likely, different patterns of tumor heterogeneity were eval-
uated by both methodologies.
Comparison between CISH and IHC results revealed six
discordant cases (16%). These same cases showed con-
cordance when comparing CISH and qRT-PCR data. Many
studies have shown high concordance between IHC and
CISH; frequently, the discordant cases were 2+ immunos-
tained [27,30-32]. In the present study, all of the samples
scored as 3+ by IHC presented HER-2 amplification by
CISH. In fact, >90% of HER-2 IHC 3+ tumors present
HER-2  gene amplification [19,33]. The concordance
between both methodologies was similar to that observed
in other studies, varying from 85% to 95.3% [24,27,34].
Differences exist in tissue screening between these two
techniques. While the IHC test requires that a minimum
of 10% of tumor cells are reactive to be considered posi-
tive, CISH scoring requires that more than 50% of tumor
cells show an increase in gene copies to be considered
amplified; according the criteria used in the present study.
It is conceivable that this difference could account for
some of the discordant results observed between IHC and
CISH. In the present study, eight cases presenting 2+ and
3+ immunostaining showed HER-2  amplification by
FISH. The two cases detected as 2+ by IHC and amplified
by FISH also presented high-level amplification using
CISH. Cases scored as 2+ and amplified by FISH were also
observed in other studies [10,35,36].
A significant correlation was detected between gene and
protein expression levels. These data are in agreement
with several reports that showed good correlation
between transcript and protein data [37-40]. However, ten
samples scored as 0 or 1+ by IHC showed HER-2 overex-
pression by qRT-PCR. The transcript quantitative analysis
revealed two classes of HER-2 overexpression: five cases
showed a median RQ = 4.09 ± 4.33 and four of these
showed gene amplification by CISH; and five other cases
Comparison between HER-2 transcript expression and lymph  node involvement (<4 nodes and ≥ 4 nodes) Figure 4
Comparison between HER-2 transcript expression 
and lymph node involvement (<4 nodes and ≥ 4 
nodes). Bars indicate the median value. P value is shown.BMC Cancer 2009, 9:90 http://www.biomedcentral.com/1471-2407/9/90
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presented a median RQ = 2.19 ± 0.21, a value very close to
the cut-off value selected (2.00). Tse et al. [39] used a cut-
off of RQ>2.2 as positive for HER-2 overexpression by
qRT-PCR when it was compared to Elisa, IHC, and FISH
on sections obtained from paraffin-embedded breast car-
cinomas.
Currently, the most widely used assay to evaluate gene sta-
tus in cases scored as 2+ immunostaining is FISH. How-
ever, qRT-PCR has emerged as a potential alternative
technique for assessing HER-2 status. The present results
demonstrated that 58.3% of the samples presenting a
score of 2+ overexpressed the transcript. Among the cur-
rent samples, four out of five patients that presented dis-
cordant results (2+ immunostaining and RQ ≤ 2.00)
showed a favorable outcome, indicating that HER-2 status
by qRT-PCR could be performed on 2+ staining tumors
with potential value regarding the management of these
patients. Of the patients presenting 2+ staining and
RQ>2.00 (eight cases), three presented metastasis, one
revealing spreading to the bone and two to the lung.
A higher concordance rate was observed between 3+ score
by IHC and overexpression by qRT-PCR. Only one sample
that presented 3+ status and HER-2 amplification showed
transcript downexpression. This case, showing a qRT-PCR
false-negative result, probably resulted from the dilution
of cells carrying amplified genes among nontumor cells
[41], although the sample was submitted to microdissec-
tion.
Concordance between the IHC and qRT-PCR results was
78.9%. The discordance between these methodologies
could include differences in the specimen used in the
experiments (paraffin-embedded and fresh tumor tissue,
respectively). Two other possible causes for discrepancy
exist: intraobserver error, due to subjectivity of the IHC
interpretation; and qRT-PCR analysis, which can cause
discrepancies particularly in the initial cycles, which
depend not only on the melting temperature of the ampli-
con, but also on the behavior of the genomic vicinity of
the amplicon [42,43]. Using PCR-based methods, the
expression of tumor- or tissue-specific genes and the pres-
ence of genetic abnormalities can be detected in a clinical
specimen with higher sensitivity (one malignant cell out
of 106–107 normal cells) than that of other techniques
such as light microscopy (one malignant cell out of 102–
103 normal cells). Using RT-PCR the nucleic acid mole-
cules can be amplified 1010-fold [for review, [44]]. More-
over, HER-2 overexpression can be detected in 0.1 cell
equivalent spiked into 8 mL of peripheral blood using
qRT-PCR and the detection limited increases to 10 and 50
cell equivalent per 8 mL in cell lines expressing intermedi-
ate and low levels of HER-2 [45].
Comparison between qRT-PCR data and CISH results
showed that the gene expression median was correlated
with gene copy number, a finding also observed by
Bergqvist et al. [46]. HER-2 gene amplification is the most
prevalent genetic mechanism driving HER-2 overexpres-
sion. The discordant cases (8.1%) showed 2+ and 3+
immunostaining, confirming the CISH results. In this
study, the concordance between qRT-PCR and FISH was
100%. High concordances were observed by other studies
[23,47].
In the present study, a high correlation rate among the
three procedures used to score HER-2 status in breast car-
cinomas was observed. The correlation between CISH and
qRT-PCR was higher than CISH and IHC, which was
higher than qRT-PCR and IHC for the samples evaluated
by all these procedures. In fact, CISH and qRT-PCR are
complementary methodologies for evaluating HER-2 sta-
tus.
No correlation was found between HER-2 expression by
IHC or gene copy number and clinicopathological data.
However, a significant association was observed between
lymph node status and HER-2 transcript expression by
qRT-PCR. Peiró et al. [48] analyzed HER-2 status by IHC
and CISH and observed a correlation with histological
grade and lymph-vascular invasion, but no association
was found with age, tumor size and Ki-67 status. Simi-
larly, the absence of correlation between HER-2 status and
clinical and pathological features has been reported in
other studies [32,43].
No statistically significant difference was observed
between ductal and lobular carcinomas evaluated by qRT-
PCR. Among the lobular carcinomas, amplification by
CISH was observed in one case, followed by HER-2 over-
expression and negative IHC staining. In a previous study,
this case was confirmed as negative for e-cadherin protein
expression and presented CDH1 promoter hypermethyla-
tion [49]. Li-Ning-T et al. [35] evaluated five invasive lob-
ular tumors and none showed amplification by CISH,
however two cases presented 2+ immunostaining.
Conclusion
In conclusion, the present results suggest that HER-2 sta-
tus can be performed by CISH and qRT-PCR analysis.
CISH combines the advantages of IHC and FISH and is a
promising practical alternative to FISH, while qRT-PCR is
reliable, semiautomated and fast; and both methodolo-
gies can be performed in most pathology laboratories.
However, there are several limitations to apply qRT-PCR
as a routine method for clinical application, including the
use of fresh frozen tissue, microdissection procedures and
the incapacity to address cell-to-cell variations. In addi-BMC Cancer 2009, 9:90 http://www.biomedcentral.com/1471-2407/9/90
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tion, the data confirm that HER-2 overexpression is asso-
ciated with a worst prognostic in human breast tumors.
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